Lentigo maligna – anatomic location as a potential risk factor for recurrences after non‐surgical treatment. (19th September 2016)

• Record Type: Journal Article
• Authors: Greveling, K.; van der Klok, Th.; van Doorn, M.B.A.; Noordhoek Hegt, V.; Prens, E.P.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 31:Number 3(2017)
• Page Start: 450
• Page End: 454
• Publication Date: 2016-09-19
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.13941
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Background: A higher incidence of lentigo maligna (LM) recurrences on the nose was previously observed in our cohort after non‐surgical treatment. Objectives: To determine histological parameters that might be related to the previously observed higher incidence of LM recurrences on the nose after non‐surgical treatment. Methods: We randomly selected 22 surgical specimens of LM on the nose and 22 on the cheek. Histopathological analysis was performed on haematoxylin and eosin stained and microphthalmia transcription factor immunohistochemically stained slides. The number of pilosebaceous units (PSU) per mm, maximum depth of atypical melanocytes along the skin appendages and maximum depth of the PSU itself were determined. Results: The nose had a significantly higher density of PSU than the cheek. The atypical melanocytes extended deeper along the PSU on the nose with a mean (SD) depth of 1.29 mm (0.48) vs. a mean depth of 0.72 mm (0.30) on the cheek ( P < 0.001). The maximum depth of the PSU on the nose was greater than on the cheek, mean (SD) depth of 2.28 mm (0.41) vs. 1.65 mm (0.82) ( P = 0.003). Conclusions: The higher recurrence risk of LM on the nose after non‐surgical treatment that we previously observed in our cohort is most likely based on a higher density of atypical melanocytes and also their deeper extension into the follicles. These results shed more light on our previous findings and learn that anatomical location is relevant for the risk of recurrence of LM after non‐surgical treatment.